Patterns of relapse and long-term outcome in patients treated with a curative intent for advanced Hodgkin lymphoma

References

• Aleman BMP, Raemaekers JMM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003;348(24):2396–2406.
   PubMed Web of Science ®Google Scholar
• Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–1799.
   PubMed Web of Science ®Google Scholar
• Kriz J, Reinartz G, Dietlein M, et al. Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin study group. Int J Radiat Oncol Biol Phys. 2015;92(1):46–53.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin study group. Lancet. 2017;390(10114):2790–2802.
   PubMed Web of Science ®Google Scholar
• Arboe B, Josefsson P, Jørgensen J, et al. Danish national lymphoma registry. Clin Epidemiol. 2016;8:577–581.
   PubMed Web of Science ®Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1861.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339(21):1506–1514.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3067.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol. 2007;25(5):571–578.
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Meignan M, et al. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257–1260.
   PubMed Web of Science ®Google Scholar
• Specht L, Yahalom J, Illidge T, ILROG, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–862.
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481.
   Web of Science ®Google Scholar
• Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35(1):1–39.
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;34(2):187–220.
   Web of Science ®Google Scholar
• Eichenauer DA, Aleman BMP, André M, et al. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol off J Eur Soc Med Oncol. 2018;29:iv19–iv29.
   PubMed Web of Science ®Google Scholar
• Sieber M, Tesch H, Pfistner B, et al. Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s lymphoma study group HD6 trial. Ann Oncol. 2004;15(2):276–282.
   PubMed Web of Science ®Google Scholar
• Press OW, Li H, Schöder H, et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816. J Clin Oncol. 2016;34(17):2020–2027.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial o. J Clin Oncol. 2011;29(32):4234–4242.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018;36(5):454–462.
   PubMed Web of Science ®Google Scholar
• Dhakal S, Biswas T, Liesveld JL, et al. Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2009;75(1):188–192.
   PubMed Web of Science ®Google Scholar
• Dharmarajan KV, Friedman DL, Schwartz CL, et al. Patterns of relapse from a phase 3 study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the children’s oncology group. Int J Radiat Oncol Biol Phys. 2015;92(1):60–66.
   PubMed Web of Science ®Google Scholar
• Aleman BMP, Raemaekers JMM, Tomiŝiĉ R, et al. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2007;67(1):19–30.
   PubMed Web of Science ®Google Scholar
• Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112(10):3989–3994.
   PubMed Web of Science ®Google Scholar
• Lockney NA, Yang JC. Radiation therapy for advanced-stage Hodgkin lymphoma. Adv Radiat Oncol. 2020;5(5):809–816.
   PubMedGoogle Scholar
• Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348(24):2386–2395.
   PubMed Web of Science ®Google Scholar
• Ricardi U, Levis M, Evangelista A, et al. OC-0502 role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial. Radiother Oncol. 2019;133:S258–S259.
   Web of Science ®Google Scholar
• Gallamini A, Rossi A, Patti C, et al. Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL/FIL HD0607 trial. J Clin Oncol. 2020;38(33):3905–3913.
   PubMed Web of Science ®Google Scholar